273 related articles for article (PubMed ID: 22027691)
41. Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.
Loveless ME; Lawson D; Collins M; Nadella MV; Reimer C; Huszar D; Halliday J; Waterton JC; Gore JC; Yankeelov TE
Neoplasia; 2012 Jan; 14(1):54-64. PubMed ID: 22355274
[TBL] [Abstract][Full Text] [Related]
42. A pumpkin polysaccharide induces apoptosis by inhibiting the JAK2/STAT3 pathway in human hepatoma HepG2 cells.
Shen W; Chen C; Guan Y; Song X; Jin Y; Wang J; Hu Y; Xin T; Jiang Q; Zhong L
Int J Biol Macromol; 2017 Nov; 104(Pt A):681-686. PubMed ID: 28634059
[TBL] [Abstract][Full Text] [Related]
43. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Hedvat M; Huszar D; Herrmann A; Gozgit JM; Schroeder A; Sheehy A; Buettner R; Proia D; Kowolik CM; Xin H; Armstrong B; Bebernitz G; Weng S; Wang L; Ye M; McEachern K; Chen H; Morosini D; Bell K; Alimzhanov M; Ioannidis S; McCoon P; Cao ZA; Yu H; Jove R; Zinda M
Cancer Cell; 2009 Dec; 16(6):487-97. PubMed ID: 19962667
[TBL] [Abstract][Full Text] [Related]
44. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
45. Casticin induces apoptosis and cytoprotective autophagy while inhibiting stemness involving Akt/mTOR and JAK2/STAT3 pathways in glioblastoma.
Yang X; Liu Z; Xu X; He M; Xiong H; Liu L
Phytother Res; 2024 Jan; 38(1):305-320. PubMed ID: 37869765
[TBL] [Abstract][Full Text] [Related]
46. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Miletic H; Enger PØ; Goplen D
J Neurooncol; 2016 Aug; 129(1):57-66. PubMed ID: 27283525
[TBL] [Abstract][Full Text] [Related]
47. Swelling-induced chloride current in glioblastoma proliferation, migration, and invasion.
Wong R; Chen W; Zhong X; Rutka JT; Feng ZP; Sun HS
J Cell Physiol; 2018 Jan; 233(1):363-370. PubMed ID: 28262948
[TBL] [Abstract][Full Text] [Related]
48. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG
Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829
[TBL] [Abstract][Full Text] [Related]
49. Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells.
De Robertis A; Valensin S; Rossi M; Tunici P; Verani M; De Rosa A; Giordano C; Varrone M; Nencini A; Pratelli C; Benicchi T; Bakker A; Hill J; Sangthongpitag K; Pendharkar V; Liu B; Ng FM; Then SW; Jing Tai S; Cheong SM; He X; Caricasole A; Salerno M
Mol Cancer Ther; 2013 Jul; 12(7):1180-9. PubMed ID: 23619303
[TBL] [Abstract][Full Text] [Related]
50. Fraxetin inhibits the growth of colon adenocarcinoma cells via the Janus kinase 2/signal transducer and activator of transcription 3 signalling pathway.
Ren S; Xing Y; Wang C; Jiang F; Liu G; Li Z; Jiang T; Zhu Y; Piao D
Int J Biochem Cell Biol; 2020 Aug; 125():105777. PubMed ID: 32504672
[TBL] [Abstract][Full Text] [Related]
51. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
52. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of the Invasion of Human Glioblastoma U87 Cell Line by Ruxolitinib: A Molecular Player of miR-17 and miR-20a Regulating JAK/STAT Pathway.
Delen E; Doganlar O; Doganlar ZB; Delen O
Turk Neurosurg; 2020; 30(2):182-189. PubMed ID: 31452174
[TBL] [Abstract][Full Text] [Related]
54. TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway.
Hou J; Lv A; Deng Q; Zhang G; Hu X; Cui H
Oncol Rep; 2019 Feb; 41(2):753-764. PubMed ID: 30431125
[TBL] [Abstract][Full Text] [Related]
55. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
56. Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
Chang HH; Cheng YC; Tsai WC; Tsao MJ; Chen Y
Cell Physiol Biochem; 2018; 48(4):1694-1702. PubMed ID: 30078005
[TBL] [Abstract][Full Text] [Related]
57. Upregulation of microRNA-133a and downregulation of connective tissue growth factor suppress cell proliferation, migration, and invasion in human glioma through the JAK/STAT signaling pathway.
Zhang P; Chen FZ; Jia QB; Hu DF
IUBMB Life; 2019 Dec; 71(12):1857-1875. PubMed ID: 31381269
[TBL] [Abstract][Full Text] [Related]
58. NF-κB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma.
McFarland BC; Hong SW; Rajbhandari R; Twitty GB; Gray GK; Yu H; Benveniste EN; Nozell SE
PLoS One; 2013; 8(11):e78728. PubMed ID: 24244348
[TBL] [Abstract][Full Text] [Related]
59. A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.
Kim BH; Yin CH; Guo Q; Bach EA; Lee H; Sandoval C; Jayabose S; Ulaczyk-Lesanko A; Hall DG; Baeg GH
Mol Cancer Ther; 2008 Sep; 7(9):2672-80. PubMed ID: 18790749
[TBL] [Abstract][Full Text] [Related]
60. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
